Evaluation of Nasal Decongestants by Literature Review
References
- U.S. Food and Drug Administration. (2012). Drug applications for over-the-counter (OTC) drugs. Retrieved February 20, 2013, from
http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/over-the-counterdrugs/default.htm - U.S. Food and Drug Administration (FDA). (2013). Over-the-Counter Medicines: What’s Right for You? Retrieved February 20, 2013, from March 09, 2013, from
https://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/understandingover-the-countermedicines/choosingtherightover-the-countermedicineotcs/ucm150299.htm - Bond, C., Blenkinsopp, A. & Raynor, D. K. (2012). Prescribing and partnership with patients. British journal of clinical pharmacology. 74(4): 581–588. DOI: 10.1111/j.1365-2125.2012.04330.x.
- Westerlund, T., Barzi, S. & Bernsten, C. (2017). Consumer views on safety of over-the-counter drugs, preferred retailers and information sources in Sweden: after re-regulation of the pharmacy market. Pharmacy practice. 15(1): 894. DOI: 10.1007/s11096-012-9724-1.
- Shankar, P. R., Partha, P. & Shenoy, N. (2002). Self-medication and non-doctor prescription practices in Pokhara valley, Western Nepal: a questionnaire-based study. BMC family practice, 3, 17. DOI:10.1186/1471-2296-3-17.
- Sleath, B., Rubin, R. H., Campbell, W., Gwyther, L. & Clark. T.(2001). Physician-patient communication about over-the-counter medications. Soc Sci Med. 53(3); 357–369. PMID: 11439819
- Sansgiry, S. S., Bhansali, A. H., Bapat, S. S. & Xu, Q. (2016). Abuse of over-the-counter medicines: a pharmacist’s perspective. Integrated pharmacy research & practice. 6: 1–6. DOI:10.2147/IPRP.S103494.
- Homedes, N. & Vgailde, A. (2001). Improving Use of Pharmaceuticals Through Patient and Community Level Intervention. Soc Sci Med. 52 (1): 99–134. PMID:11144920
- Parikh, D., Sattigeri, BM., Kumar, A. & Brahmbhatt, S. (2013). A survey study on use of over the counter (OTC) drugs among medical students, nursing and clerical staff of a tertiary care teaching rural hospital. Int J Res Med Sci. 1(2): 83–86. DOI: 10.5455/2320-6012.
- Zaffani, E. R., Kamimura, GF., Maniglia, AJV. & Fernades, AM. (2007) Perfil epidemiológico dos pacientes usuários de descongestionantes nasais tópicos do ambulatório de otorrinolaringologia de um hospital universitário. Arq. Ciênc. Saúde. 14(2); 95–98.
- Baumann, LM., Romero, KM., Robison, CL., Hansel, NN., Gilman, RH., Hamilton, RG., Lima, JJ., Wise, RA. & Checkley, W.(2015). Prevalence and risk factors for allergic rhinitis in two resource-limited settings in Peru with disparate degrees of urbanization. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 45(1): 192–9. DOI: 10.1111/cea.12379.
- Bernstein, DI., Schwartz, G. & Bernstein, JA. (2012). Allergic Rhinitis: Mechanisms and Treatment. Immunol Allergy Clin North Am. 36(2): 261–78. DOI: 10.1016/j.iac.2015.12.004.
- Corboz, M.R., Rivelli, M.A., Mingo, G.G., Mcleod, R.L., Varty, L. & Jia Y.A. (2008). Mechanism of decongestant activity of alpha 2-adrenoceptor agonists. Pul. Pharmacol. 21(3): 449–454. DOI: 10.1016/j.pupt.2007.06.007.
- Doshi, J. (2009). Rhinitis medicamentosa: what an otolaryngologist needs to know. Eur. Arch. Otorhinolaryngol. 266(5): 623–625. DOI:10.1007/s00405-008-0896-1.
- Servidoni, AB., Coelho, L., Navarro, ML., Ávila, FG. & Mezzalira R. (2006). Perfil da automedicação nos pacientes otorrinolaringológicos. Rev. Bras. Otorrinolaringol. 72(1): 83–88. DOI: org/10.1590/S0034-72992006000100013.
- Lenz, D., Cardoso, KS., Bitti, AC. & Andrade, TU. (2011). Evaluation of the use of topic nasal decongestants in university students from health sciences courses. Brazilian Journal of Pharmaceutical Sciences. 47(4): 761–767. DOI: org/10.1590/S1984-82502011000400013.
- Eccles, R., Eriksson, M., Garreffa, S. & Chen. SC. (2008). The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology. 22(5): 491–496. DOI: 10.2500/ajr.2008.22.3202.
- Lui, CT. (2017). Prescription practice of antihistamines for acute upper respiratory tract infections in pediatric patients in a local emergency department in Hong Kong. World J Emerg Med. 8(1): 47–54. DOI: 10.5847/wjem.j.1920–8642.
- Zeynettin, K. & Abdullah, T., (2013). Adverse Cardiac Effects of Decongestant Agents. Eur J Gen Med. 10(1): 32–35. DOI:
https://doi.org/10.29333/ejgm/82301 - ANSM - Juillet 2013. Plan d’action sur les médicaments contenant des vasoconstricteurs à visée décongestionnante. Retrieved ANSM - Juillet 2013, from
https://ansm.sante.fr/var/ansm_site/storage/original/application/c6285e0a4e1f950eaa262d4d788f134c.pdf - Hallas, J., Bjerrum, L. Stovring, H. & Andersen, M. (2008). Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study. Am J Epidemiol. 168(8): 966–73. DOI: 10.1093/aje/kwn191.
- Stewart, M., Ferguson, B. & Fromer, L. (2010). Epidemiology and burden of nasal congestion. International journal of general medicine. 3: 37–45. Published 2010 Apr 8.
- Mortuaire, G., de Gabory L., François, M., Massé, G., Bloch, F., Brion, N., Jankowski R. & Serrano, E. (2013). Rebound congestion and rhinitis medicamentosa: nasal decongestants in clinical practice. Critical review of the literature by a medical panel. Eur Ann Otorhinolaryngol Head Neck Dis. 130(3): 137–144. doi: 10.1016/j.anorl.2012.09.005.
- Eccles R. (2006). Substitution of phenylephrine for pseudoephedrine as a nasal decongestant. An illogical way to control methamphetamine abuse. British journal of clinical pharmacology. 63(1): 10–4. DOI: 10.1111/j.1365-2125.2006.02833.x
- Eccles, R., Martensson, K. & Chen, SC. (2010). Effects of intranasal xylometazoline, alone or in combination with ipratropium, in patients with common cold. Curr Med Res Opin. 26(4): 889–99. DOI: 10.1185/03007991003648015.
- Mortuaire, G., de Gabory, L., François, M., Massé, G., Bloch, F., Brion, N., Jankowski, R.& Serrano.E. (2013). Effet rebond et rhinite aux vasoconstricteurs nasaux en pratique clinique. Revue critique de la littérature par un groupe d’experts. Annales Françaises d’Oto-Rhino-Laryngologie et de pathologie cervico-faciale. 130 (3): 140–148. Doi : 10.1016/j.aforl.2012.11.007.
- Eccles, R., Jawad, MS., Jawad, SS., Angello, JT. & Druce, HM. (2005). Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. Am J Rhinol. 19(1): 25–31. DOI:10.1177/194589240501900105.
- ANSM. Commission Nationale de Pharmacovigilance du 20 novembre 2012.
http://www.ansm.sante.fr/var/ansm_site/storage/original/application/c9e15dee904acc094f9b909eea1634a2.pdf - Nathan, R.A., Finn AF Jr., La Force, C., Ratner, P., Chapman, D., de Guia, EC., Hewlett, D. & Kramer, B. (2006). Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study. Ann Allergy Asthma Immunol. 97(3): 389–396. DOI:10.1016/S1081-1206(10)60806-X.
- Browning, MG., Seddon, JO., Yung, LT. & Gough, G. (2011). An unusual case of systemic cardiovascular side effects from the application of over-the-counter nasal decongestion drops. BMJ Case Rep. 2011; 2011:bcr0620103078. Published 2011 Mar 24. DOI: 10.1136/bcr.06.2010.3078.
- Rimsza, M.E. & Newberry, S. (2008). Unexpected infant deaths associated with use of cough and cold medications. Pediatrics. 122(2): 318–322. DOI: 10.1542/peds.2007-3813.
- 33.
Abood, E. A., Scott, J., & Wazaify, M. (2018). User Experiences of Prescription and Over-The-Counter Drug Abuse in Aden City, Yemen. Pharmacy (Basel, Switzerland), 6(3): 99. DOI:
10.3390/pharmacy6030099.
AboodE. A. ScottJ. WazaifyM. 2018 User Experiences of Prescription and Over-The-Counter Drug Abuse in Aden City, Yemen Pharmacy (Basel, Switzerland) 6 3 99 10.3390/pharmacy6030099
- Laccourreye, O., Werner, A., Giroud, J.P., Couloigner, V., Bonfils, P. & Emmanuelle Bondon-Guitton. (2015). Apport, dangers et limites de l’éphédrine et de la pseudoéphédrine en tant que décongestionnant nasal. Annales françaises d’Oto-rhino-laryngologie et de Pathologie Cervico-faciale. 132(1): 28–31. DOI: 10.1016/j.aforl.2014.11.007.
- Atkinson, HC., Stanescu, I. & Anderson, BJ.(2014). Increased phenylephrine plasma levels with administration of acetaminophen. N Eng J Med. 370(12): 1171–1172. doi: 10.1056/NEJMc1313942.
- Vaidyanathan, S., Williamson, P., Clearie, K., Khan, F. & Lipworth, B.(2010). Fluticasone Reverses Oxymetazoline-induced Tachyphylaxis of Response and Rebound Congestion. 182 (1); 19–24. DOI: 10.1164/rccm.200911-1701OC.
- Pray SW, Pray JJ. Safe Use of Nasal Decongestants. US Pharmacist. 2004;29(7).
- Fabi, M., Formigari, R. & Picchio FM. (2009). Are nasal decongestants safer than rhinitis? A case of oxymetazoline-induced syncope. Cardiol Young. 19: 633–634. DOI: 10.1017/S1047951109990722.
- Dokuyucu, R., Gokce, H., Sahan, M., Sefil, F., Tas, ZA., Tutuk, O., Ozturk. A., Tumer, C. & Cevik, C. (2015). Systemic side effects of locally used oxymetazoline. Int J Clin Exp Med. 8 (2): 2674–2678. Published online 2015 Feb 15.
- 40.
Antonicelli, L., Micucci, C., Voltolini, S., Senna, GE., Di Blasi, P., Visonà, G., De Marco, R. & Bonifazi F. (2007). Relationship between ARIA classification and drug treatment in allergic rhinitis and asthma. Clin Exp Allergy. 62(9): 1064–1070. DOI:
10.1111/j.1398-9995.2007.01470.x
AntonicelliL. MicucciC. VoltoliniS. SennaGE. Di BlasiP. VisonàG. De MarcoR. BonifaziF. 2007 Relationship between ARIA classification and drug treatment in allergic rhinitis and asthma Clin Exp Allergy 62 9 1064 1070 10.1111/j.1398-9995.2007.01470.x
- Giavina-Bianchi, P., Agondi, R., Stelmach, R., Cukier, A. & J.Kalil. (2008). Fluticasone furoate nasal spray in the treatment of allergic rhinitis. Ther Clin Risk Manag. 4(2): 465–472.
- Martin, BG., Ratner, PH., Hampel, FC., Andrews, CP., Toler, T., Wu, W., Faris, MA. & Philpot, EE. (2007). Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc. 28 (2): 216–225. DOI:
https://doi.org/10.2500/aap.2007.28.2983 - Hampel, FC. Jr, Jacobs, R., Martin, B., Toler, T., Ellsworth, A. & Philpot, E. (2007). Once-daily fluticasone furoate nasal spray (FF) provides 24-hour symptom relief in subjects with seasonal allergic rhinitis (SAR) caused by mountain cedar pollen. J Allergy Clin Immunol. 119(1): 304–5. DOI:
https://doi.org/10.1016/j.jaci.2006.12.563 - Juel-Berg, N., Darling, P., Bolvig, J., Foss-Skiftesvik, MH., Halken, S. & Winther, L.(2017). Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: A systematic review and meta-analysis. Am J Rhinol Allergy. 31(1): 19–28. DOI: 10.2500/ajra.2016.30.4397.
- Meltzer, EO. (2007). Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 98(1); 12–21. DOI: 10.1016/S1081-1206(10)60854-X.
- Verret, DJ. & Marple, BF.(2005). Effect of topical nasal steroid sprays on nasal mucosa and ciliary function. Curr Opin Otolaryngol Head Neck Surg. 13(1): 14–18.
- Riechelmann, H., Deutschle, T., Stuhlmiller, A., Gronau, S. & Bürner, H. (2004). Nasal toxicity of benzalkonium chloride. Am J Rhinol. 18(5): 291–299.
https://doi.org/10.1177/194589240401800506 - Peter, Graf. & Hans, Hallén. (1996). Effect on the Nasal Mucosa of Long Term Treatment With Oxymetazoline, Benzalkonium Chloride, and Placebo Nasal Sprays. The Laryngoscope. 106 (5 Pt 1), 605–609. DOI:10.1097/00005537-199605000-00016.
- Dimova, S., Mugabowindekwe, R., Willems, T. Brewster, ME., Noppe, M., Ludwig, A., Jorissen, M., Augustijns, P. (2003). Safety-assessment of 3-methoxyquercetin as an anthirhinoviral compund for nasal application: effect on ciliary beat frequency. Int J Pharm. 263(1): 95–103.
- Meltzer, EO. (2007). Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 98(1): 12–21. DOI: 10.1016/S1081-1206(10)60854-X.
- Oppliger, R. & Hauser, C. (2004). Anaphylaxis after injection of corticosteroid preparations-carboxymethylcellulose as a hidden allergen [in German]. J Dtsch Dermatol Ges. 2(11): 928–930.
- Kirtsreesakul, V., Wongsritrang, K. & Ruttanaphol, S. (2011). Clinical efficacy of a short course of systemic steroids in nasal polyposis. Rhinology. 49(5): 525–532. DOI: 10.4193/Rhino11.140.
- Vaidyanathan, S., Barnes, M., Williamson, P., Hopkinson, P., Donnan, P.T. & Lipworth, B. (2011). Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids: A randomized trial. Ann Intern Med. 154 (5): 293–302. DOI: 10.7326/0003-4819-154-5-201103010-00003.
- Sastre, J. & Mosges, R. (2012). Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 22(1): 1–12.
Language: English
Page range: 181 - 188
Submitted on: Dec 16, 2018
Accepted on: Jan 17, 2019
Published on: Nov 4, 2019
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2019 Stasa Petkovic, Ivana Maletic, Sonja Djuric, Ninoslava Dragutinovic, Olivera Milovanovic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.